Phase 1/2 Trial of CAR-T Cell Immunotherapy in Metastatic, Mesothelin-Expressing Cancer

Share this content:
Researchers are evaluating whether CAR-T cell immunotherapy that targets mesothelin is safe and effective among patients with mesothelin-expressing tumors.
Researchers are evaluating whether CAR-T cell immunotherapy that targets mesothelin is safe and effective among patients with mesothelin-expressing tumors.

Title: Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes1

Principal Investigator: Steven A Rosenberg, MD, National Cancer Institute (NCI)

Description: For this open-label, single-group assignment phase 1/2 study (ClinicalTrials.gov Identifier: NCT01583686), researchers are evaluating whether chimeric antigen receptor (CAR)-T cell immunotherapy that targets mesothelin is safe and effective among patients with metastatic, mesothelin-expressing tumors.

Patients with mesothelioma or cervical, pancreatic, ovarian, or lung cancer will be enrolled to receive fludarabine, anti-mesothelin CAR-T cell therapy, cyclophosphamide, and aldesleukin. All patients will undergo leukapheresis prior to therapy; white blood cells will modified to target mesothelin.

The primary outcomes are safety and anti-tumor efficacy. The estimated number of enrolled patients is 136.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01583686.

Status: This study is open and recruiting patients as of April 27, 2018.

This study is sponsored by the NCI.

Reference

  1. Clinicaltrials.gov. CAR T cell receptor immunotherapy targeting mesothelin for patients with metastatic cancer. NCT01583686. https://clinicaltrials.gov/ct2/show/NCT01583686. Accessed April 27, 2018.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs